Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma

NCT02229071 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

HCC

Interventions

DRUG: Donafenib(200mg)
DRUG: Donafenib(300mg)

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Collaborators

[object Object]